10-Q: Yubo International Biotech Reports Q3 2024 Results with Revenue Decline and Increased Operating Expenses

Yubo International Biotech's Q3 2024 results show a significant decrease in revenue and an increase in operating expenses, leading to a net loss.

Summary

• Yubo International Biotech reported its financial results for the third quarter of 2024, showing a significant decrease in revenue to $0 from $428,510 in the same period last year.
• The company's cost of goods sold also decreased to $0 from $84,428 year-over-year, due to the lack of sales.
• Operating expenses increased to $532,764 from $337,659 year-over-year, driven by higher occupancy and employee compensation costs.
• The company's net loss for the quarter was $621,053, compared to a net income of $6,293 in the same quarter of 2023.
• For the nine months ended September 30, 2024, revenue was $3,488, a decrease from $582,390 in the same period of 2023.
• The cost of goods sold for the nine-month period was $827, down from $181,267 year-over-year.
• Operating expenses for the nine-month period increased to $1,415,282 from $1,078,508 year-over-year.
• The net loss for the nine months ended September 30, 2024, was $1,628,906, compared to a net loss of $677,701 in the same period of 2023.
• The company had cash and equivalents of $8,034 and a negative working capital of $3,765,630 as of September 30, 2024.

Sentiment

Score: 2

Explanation: The document indicates a significant decline in financial performance, with a substantial decrease in revenue, increased operating expenses, and a net loss. The company's going concern status and reliance on future capital raises further contribute to a negative sentiment.

Positives

• The company had proceeds from the sale of equipment of $118,431 during the nine months ended September 30, 2024.
• The company received a capital contribution to a subsidiary by non-controlling interest of $297,760 during the nine months ended September 30, 2024.

Negatives

• The company experienced a significant decrease in revenue for both the three and nine-month periods ending September 30, 2024.
• Operating expenses increased substantially for both the three and nine-month periods ending September 30, 2024.
• The company reported a net loss for both the three and nine-month periods ending September 30, 2024.
• The company has a negative working capital of $3,765,630 as of September 30, 2024.
• The company has a limited amount of cash on hand, with only $8,034 as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional capital resources.
• The company's VIE structure in China carries risks related to regulatory compliance and potential penalties.
• The company faces risks associated with regulatory approvals on offshore offerings, antimonopoly regulatory actions, and oversight on cybersecurity and data privacy.
• The company's reliance on a limited number of customers poses a risk to its revenue stream.
• The company's ability to pay dividends is primarily dependent on receiving distributions from its subsidiaries and VIE, which are subject to PRC regulations.
• The company's operations are subject to the Holding Foreign Companies Accountable Act, which could lead to delisting if the company's auditor is not inspected by the PCAOB.
• The company's operations are subject to cybersecurity review measures in China, which could lead to disruptions and penalties.
• The company's operations are subject to the PRC Personal Information Protection Law, which could lead to penalties for non-compliance.
• The company's operations are subject to the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, which could lead to penalties for non-compliance.

Future Outlook

The company believes that its cash on hand and working capital will be sufficient to meet its and Yubo Beijing's anticipated cash requirements through 2024. The company intends to continue working toward identifying and obtaining new sources of financing and intends to raise additional capital in the fourth quarter of 2024.

Management Comments

• Management plans to obtain additional capital from management and significant shareholders to meet operating expenses.
• Management is seeking third-party equity and/or debt financing.

Industry Context

The company operates in the biotechnology sector, specifically focusing on stem cell research and development. The industry is characterized by high research and development costs, regulatory hurdles, and competition. The company's reliance on a VIE structure in China is a common practice for foreign investment in certain industries but carries unique risks.

Comparison to Industry Standards

• The company's significant revenue decline and increased operating expenses are concerning when compared to industry standards for biotech companies.
• Many biotech companies at a similar stage of development are focused on research and development and may not have significant revenue, but the lack of revenue and increase in expenses is a concern.
• The company's negative working capital and limited cash on hand are below industry benchmarks for companies seeking to expand and commercialize their products.
• The company's reliance on related party loans is not uncommon for early-stage companies, but the amount of debt is a concern.
• The company's VIE structure is a common practice for foreign investment in China, but the associated risks are a concern.

Related Party Transactions

• The company has payables due to Mr. Jun Wang, Mr. Yang Wang, Ms. Huang Li, and Mr. Jin Wei, all of whom are related parties.
• The company has a due from related party receivable from Beijing Zhenhuikang Biotechnology Co., LTD.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial performance and going concern status.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be affected by the company's ability to continue operations and provide products and services.
• Suppliers and creditors face risks related to the company's ability to meet its obligations.

Next Steps

• The company intends to continue working toward identifying and obtaining new sources of financing.
• The company intends to raise additional capital in the fourth quarter of 2024.

Key Dates

Keywords

Biotech, Stem Cell, China Operations, Financial Results, Revenue Decline, Operating Expenses, Net Loss, Going Concern, VIE Structure, Regulatory Risks, Cybersecurity, Data Privacy, Capital Raise